Skip to main content

Share story

Products

Motherson agrees to buy control of Rotary Connectors at ₹500.4 crore value

Samvardhana Motherson Acquires 50.1% Stake in Rotary Connectors for Rs 500 Crore Image: Primary
Samvardhana Motherson International has agreed to acquire 50.1% of Bengaluru-based Rotary Connectors through its Adsys Tech subsidiary, valuing the aerospace and defense connector maker at ₹500.4 crore. The transaction is expected to close in the fourth quarter of fiscal 2027, subject to closing conditions. Motherson would gain authority to appoint a majority of Rotary Connectors' directors, while its current promoters would retain 49.9%. Rotary Connectors operates three Bengaluru factories and makes military-grade circular connectors and electrical interconnection systems. Its unaudited turnover increased from ₹75.2 crore in fiscal 2024 to ₹123.5 crore in fiscal 2026.
Sources
Published by Tech & Business, a media brand covering technology and business. This story was sourced from whalesbook.com and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
AI Products
AI Products

Tech groups use residual-value guarantees to lower AI financing costs

Large technology companies are increasingly using residual-value guarantees to finance AI equipment off their balance sheets, the Financial Times reports. The guarantees apply the companies' credit strength to the hardware's futur...

Capital Products
Capital Products

xFarm buys Sibium Analytics, adding 8 million monitored hectares

Agricultural software provider xFarm Technologies has acquired Brazil-based Sibium Analytics, adding more than 8 million monitored hectares and nine large sugarcane producers to its platform. xFarm already served more than 600,000...

AI Capital
AI Capital

Altis Labs raises $25 million for oncology-trial AI

Altis Labs raised a $25 million Series A, CEO Felix Baldauf-Lenschen told Axios Pro. The AI software company analyzes CT scans taken during oncology trials and produces predictions tied to patient survival, supporting a drug-devel...